SYDNEY, Wednesday 04 April 2018

Cellmid Limited (ASX:CDY) (the Company) advises that it has entered into an agreement with Labo International S.r.l to undertake the exclusive distribution of Fillerina®, a market leading Swiss anti-aging skincare brand, in Australia and New Zealand for up to an initial five years. Relevant terms include joint distribution and sales targets and a close marketing collaboration between the parties.

Fillerina® is a world first, patented dermo-cosmetic filler treatment, which has been scientifically proven to reduce facial wrinkles, deliver measurable filling effect, increase facial volumes and decrease the clinical signs of skin aging. It is the first non-invasive filler treatment with clinical study results published in a peer reviewed article and it is a market leader in innovative, high-performance skincare within the fast-growing anti-aging cosmetics space globally.

Click here to